Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Common Equity: 2016-2025

Historic Common Equity for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $607.2 million.

  • Tg Therapeutics' Common Equity rose 216.00% to $607.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $607.2 million, marking a year-over-year increase of 216.00%. This contributed to the annual value of $222.4 million for FY2024, which is 38.54% up from last year.
  • Tg Therapeutics' Common Equity amounted to $607.2 million in Q3 2025, which was up 119.66% from $276.4 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Common Equity registered a high of $607.2 million during Q3 2025, and its lowest value of $27.4 million during Q1 2023.
  • Moreover, its 3-year median value for Common Equity was $177.6 million (2024), whereas its average is $206.0 million.
  • In the last 5 years, Tg Therapeutics' Common Equity surged by 33,010.94% in 2021 and then crashed by 83.90% in 2023.
  • Quarterly analysis of 5 years shows Tg Therapeutics' Common Equity stood at $237.2 million in 2021, then crashed by 75.30% to $58.6 million in 2022, then skyrocketed by 173.95% to $160.5 million in 2023, then soared by 38.54% to $222.4 million in 2024, then surged by 216.00% to $607.2 million in 2025.
  • Its Common Equity was $607.2 million in Q3 2025, compared to $276.4 million in Q2 2025 and $237.3 million in Q1 2025.